Aug 21, 2024 / 02:00PM GMT
Operator
Greetings, and welcome to the Nykode Therapeutics Q2 2024 financial results presentation. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to introduce your host, CEO, Michael Engsig. Please go ahead, sir.
Michael Engsig - Nykode Therapeutics ASA - Chief Executive Officer
Thank you very much, Kevin and also from our side, a very warm welcome to all participants at this webcast to go through the second quarter of Nykodes.
Of course, with me today, I'm pleased to have Agnete Fredriksen, Chief Scientific Officer and Head of Business Development. Harald Gurvin, our Chief Finalcial Officer; and Klaus Edvardsen, Head of Research and Development. We assume your're all familiar with our forward-looking statements. So on that note, we'll just quickly skip forward.
So as first quarter has been another eventful quarter. And in addition to that, we have this morning also announced a strategic repositioning, which we'll take you further through.
So I'm going to give you a brief run-on of the
Q2 2024 Nykode Therapeutics ASA Earnings Call Transcript
Aug 21, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers